IBO - impactbiomedinc.com Income before deduction of interest, taxes and amortization
Impact BioMedical Inc (IBO) possesses moderate pricing power in the biosafety segment due to patents on plant-based compounds. The cash EBITDA trend clearly demonstrates current efficiency, with the metric reaching the level of 0.00. The Linebacker antiseptic line supports a network of licensees under FDA supervision, however, asset fragmentation and a rapid cash burn create significant financial risks.
Summary analytical data breakdowns for Impact BioMedical Inc (IBO)
- current price and projected stock value:
- market capitalization statistics:
- book capitalization information:
- business debt structure and liquidity details:
Total Debt to Capital Coefficient Impact BioMedical Inc|IBO - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio impactbiomedinc.com|IBO - Company Debts|Debts to Book Capitalization Ratio Impact BioMedical|IBO - Company Long-Term Debts|Company Short-Term Debts Impact BioMedical|Quick Liquidity Indicator impactbiomedinc.com
- earnings and market multiples details:
IBO - Net Income|Future Net Profit Impact BioMedical Inc|IBO - Price to Earnings Ratio|Future Price to Earnings Multiple Impact BioMedical, Inc.|IBO - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Impact BioMedical|IBO - Operating profit EBITDA|Net earnings per share for the last four quarters Impact BioMedical|IBO - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months impactbiomedinc.com|IBO - Earnings per share growth in current year|Expected earnings per share growth for next year Impact BioMedical Inc
Analysis of all company metrics:Impact BioMedical, Inc., IBO
Integrating ESG standards into the management of biotechnological developments at Impact BioMedical Inc. (IBO) requires strict control over bioethics and safety costs. By analyzing the company's EBITDA, an investor assesses operating profit before depreciation and interest, which allows for the isolation of net cash flow from debt burdens and determines the actual efficiency of business scaling, confirming the asset's fundamental stability.
Who Impact BioMedical Inc competes with
Company profit before taxes, interest and amortization HLN (Haleon Corp)|Kenvue Inc. - Operating profit EBITDA|Income before deduction of interest, taxes and amortization VRNA (veronapharma.com)|MENS: Operating profit EBITDA|Profit before interest, taxes and amortization Ligand Pharmaceuticals Incorporated (LGND)|Profit before payment of interest, taxes and amortization Amneal Pharmaceuticals Inc|PRGO: Income before deduction of interest, taxes and amortization|Operating profit EBITDA ALVO|Operating income before deduction of amortization liquidia.com|Profit before payment of interest, taxes and amortization Galapagos GLPG|ANIP - Operating profit before deduction of amortization|MNKD - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization AMPH|PCRX: Operating profit EBITDA|ars-pharma.com (SPRY) - Operating profit EBITDA|TBPH (Theravance Biopharma, Inc.) - Operating profit EBITDA|Operating profit before deduction of amortization Aquestive Therapeutics Inc (AQST)|Operating profit before deduction of amortization SCPH (scPharmaceuticals Inc.)|Company profit before taxes, interest and amortization TECX|Tonix Pharmaceuticals - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization SXTC|Eupraxia Pharma - Operating profit EBITDA|BHST: Profit before payment of interest, taxes and amortization|EXOZ: Operating profit EBITDA|ORMP - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Entera Bio Ltd|Profit before interest, taxes and amortization ipatherapeutics.com HYFT|Profit before payment of interest, taxes and amortization ABVC BioPharma, Inc. (ABVC)|Operating profit before deduction of amortization Cumberland Pharmaceuticals Inc CPIX|Operating profit EBITDA QNTM (Quantum BioPharma Limited)|FibroGen Corporation (FGEN) - Profit before interest, taxes and amortization|Telomir Pharmaceuticals - Operating profit EBITDA|RANI (Rani Therapeutics) - Operating profit before amortization|SNYR: Operating profit EBITDA|RLYB - Operating income before deduction of amortization|LEXX (Lexaria Bioscience Corp) - Operating profit EBITDA|Operating profit before deduction of amortization Pulmatrix Corporation (PULM)|Operating profit EBITDA PTHL|Operating profit EBITDA aptorumgroup.com (APM)|Profit before payment of interest, taxes and amortization Lyra Therapeutics LYRA|TNF Pharmaceuticals Inc. - Profit before payment of interest, taxes and amortization|YCBD: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization PRFX (PainReform Corp)|CYTO: Operating profit EBITDA|LIPO - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization OptiNose|Operating profit before amortization PIRS (Pieris Pharmaceuticals Inc)|Operating profit EBITDA PROC|Operating profit before deduction of amortization Petros Pharma PTPI|Operating profit EBITDA QLI (Qilian International)|Operating income before deduction of amortization acelyrin.com (SLRN)|TFF Pharmaceuticals, Inc. - Operating profit EBITDA
